CPhI Worldwide, organised by UBM Live, celebrates the closing of its most successful show to date with pre-audit figures estimating more than 34,000 attendees and 2,200 exhibitors. Held in Frankfurt, the show hosted senior-level decision makers and key players from 140+ countries representing every step of the pharmaceutical supply chain from drug discovery to finished dosage.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/63503-UBM-live-cphi-worldwide
Eisai Inc. announced today that BELVIQ (pronounced BEL-VEEK) will be available to eligible patients by prescription in the United States beginning June 11.
BELVIQ was approved by the U.S. Food and Drug Administration on June 27, 2012 to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of 30 kg/m² or greater (obese), or BMI of 27 kg/m² or greater (overweight) with at least one weight-related medical condition such as high blood pressure, high cholesterol, or type 2 diabetes. It is not known if BELVIQ is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products, nor is it known if BELVIQ changes your risk of heart problems or stroke, or of death due to heart problems or stroke.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/60316-eisai-belviq-civ-chronic-weight-management-tablets-for-overweight-adults
Kelley longed for a normal life, to go to college, to have normal friends, and to work a nice desk job. When an unknown predator starts a killing spree, she finds herself drug back into a world that includes vampires, werewolves, and her ex-husband. Find out more at http://saramdrake0.blogspot.com/. Family Heir: A Bigfoot Novel by Sara M. Drake book trailer. Paranormal/Urban Fantasy
Meijer announced today it is launching its new Consumer Drug Take-Back Program by installing secure in-store kiosks designed to help customers safely and properly dispose of unused or expired prescription drugs at no cost. Customers can find the easily identifiable kiosks in the pharmacy area in all 241 Meijer supercenters across the Midwest.
“Meijer is thrilled to be one of the first in our industry to provide a secure and convenient prescription drug take-back program at all stores in the communities we serve,” said Jason Beauch, Vice President of Meijer Pharmacy. “The Meijer Drug Take-Back Program allows our customers to remove the risk of an unforeseen accident occurring with expired or unused medications, while enabling them to properly dispose prescription drugs and reducing the possibility of creating a public health hazard.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8497051-meijer-consumer-drug-take-back-program/
Click: http://rhettmay.com/ “A Little White Powder Under Your Nose” by Rhett May. A video about a crazy lady selling her body to finance here drug addiction!
Since ancient times, the egg has been regarded as a symbol of new life and has been associated with springtime celebrations, such as Easter and Passover. But, even during festive occasions, eggs can cause food poisoning (also called foodborne illness) if they are not handled properly. That’s why the U.S. Food and Drug Administration (FDA) reminds consumers to handle fresh eggs safely during their springtime celebrations and throughout the year.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7231951-u-s-fda-egg-safety/
ILEX Consumer Products Group, a Baltimore-based company which owns and manages health and beauty as well as over the counter (OTC) drug brands, launched di-gel, a new antacid/anti-gas brand, just in time for all the overindulging and stress of the holidays.
The new digestive aid, which is being promoted with integrated TV and digital advertising, grassroots and public relations, launched with the brand tagline
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of Fluzone® (Influenza Vaccine) for the 2016-2017 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA) for shipment. This represents the first of more than 65 million total doses of seasonal influenza vaccine manufactured by Sanofi Pasteur that will be delivered to U.S. health care providers and pharmacies beginning in July and continuing throughout the remainder of the year. Sanofi Pasteur plans to increase its supply to respond to the shifting pediatric public health needs.
Seasonal influenza activity typically occurs between October and May and peaks between December and February. However, influenza activity peaked noticeably late last season occurring in early March 2016.1 Influenza seasons are always unpredictable as new influenza strains emerge and strain activity fluctuates throughout the year, making timely vaccination even more important to help protect against the virus, especially for seniors, young children and infants six months of age and older.
To view the multimedia release go to:
http://www.multivu.com/players/English/7842051-sanofi-pasteur-influenza-vaccine/
Just back from rehab, Mary Rose returns to her regular hang-out in pursuit of her “would-be” soul mate, Ryan. She is devastated when he shows up with another girl… and not just any girl either… a really pretty hippie girl, who is older, and maybe even cooler. The True Diary of Mary Rose. Find out more at http://dearnobodydiary.com non-fiction/ YA
Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
Abbott announced today the U.S. Food and Drug Administration approval and launch of the iDesign Advanced WaveScan Studio System. The system acts as the "brain" of the LASIK procedure, generating a high-definition scan that measures and maps irregularities of the eye that may impact vision. From these measurements, the iDesign System creates an accurate and personalized LASIK treatment plan based on the unique "blueprint" of each person’s eyes.
The iDesign System captures more than 1,200 micro readings of the eye, as well as identifying the shape of the cornea, its curvature, how light passes through the eye and pupil diameter under different lighting conditions – all in one, three-second scan that can be used to precisely correct vision.
The development of the sensor technology within the iDesign System was the result of an earlier discovery by Abbott scientists, which NASA used to accurately measure and shape the mirrors in the James Webb Space Telescope to ensure it will transmit high resolution images of deep space back to earth. The telescope is scheduled to launch in 2018.
To view the Multimedia News Release, please go to http://www.multivu.com/players/English/7571951-abbott-idesign-system-3-d-eye-map/
ACCU-CHEK Aviva Expert offers people with diabetes a new and easy way to simplify complex calculations to deliver precise insulin dosing advice.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the ACCU-CHEK® Aviva Expert system, the first and only blood glucose meter system with a built-in insulin calculator to be approved by the U.S. Food and Drug Administration (FDA), is now available by prescription. The device represents a significant advancement in blood glucose meter technology for people with diabetes who take multiple daily insulin injections. The meter’s integrated bolus calculator provides easy-to-use and reliable dose recommendations based on automated calculations, eliminating the need for manual dosing calculations and estimations.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322751-roche-accu-chek-aviva-expert-blood-glucose-meter-now-available/
